Syngenta Paraquat Lawsuit

Corporate history

Paraquat was developed and commercialized by Imperial Chemical Industries (ICI) in the United Kingdom in the early 1960s. ICI's agrochemicals division was spun off as Zeneca in 1993, then merged with the agrochemicals divisions of Novartis in 2000 to form Syngenta AG, headquartered in Basel, Switzerland. In 2017, Syngenta was acquired by ChemChina(China National Chemical Corporation), a state-owned Chinese enterprise. Through every corporate iteration, paraquat — sold primarily as Gramoxone — has been a flagship product.

Switzerland banned paraquat in 1989

Syngenta is headquartered in Switzerland — a country that banned paraquat in 1989, decades before the company stopped manufacturing and selling it for U.S. agricultural use. Switzerland is one of more than 60 countries that have banned paraquat, including the European Union, China, Brazil, and most major agricultural economies outside the United States.

Internal knowledge of risk

Plaintiffs' counsel in the paraquat MDL and in the Philadelphia mass tort program have developed an extensive evidentiary record on what Syngenta and its corporate predecessors knew about the paraquat-Parkinson's link and when. Internal documents and depositions have featured prominently in motion practice. While specific document quotations are subject to protective orders, the general pattern — long-standing knowledge of the Parkinson's association, inadequate label warnings, and continued aggressive marketing — is well-documented in public filings.

Litigation conduct

Syngenta has aggressively defended paraquat litigation across multiple fronts. Notable conduct:

• Daubert challenges on plaintiffs' causation experts in MDL 3004
• Jurisdictional challenges to Pennsylvania's consent-by-registration statute — denied by the U.S. Supreme Court in October 2025
• Preemption arguments under FIFRA — to be sharpened depending on Monsanto v. Durnell's resolution
• Settlement framework announcement in April 2025
• Courthouse-steps settlement of the January 2026 Philadelphia bellwether
• March 2026 announcement discontinuing U.S. paraquat production

The April 2025 settlement framework

In April 2025 Syngenta publicly announced a settlement framework covering a substantial portion of pending federal paraquat claims. The framework structures resolution through a qualified settlement fund with points-based allocation. It does not extinguish liability for cases that opt out, and it does not bind Chevron.

Pennsylvania state court claimants with strong facts often consider opting out and prosecuting in Philadelphia — where jury composition and faster pace support higher expected recovery.

March 2026: U.S. production discontinuation

In March 2026, Syngenta announced that it would discontinue U.S. production of paraquat. The company framed the decision in commercial terms; plaintiffs' counsel pointed to mounting litigation costs and reputational pressure. Existing stocks will continue to be sold and applied until exhausted under EPA Restricted Use rules.

Discontinuation does not extinguish liability for past exposures. Most paraquat Parkinson's plaintiffs were exposed decades before diagnosis. The discontinuation is forward-looking; product liability for historical exposures persists.

What this means for your claim

Syngenta is the principal defendant on the manufacturing side. Chevron is a co-defendant as the historical U.S. distributor of Gramoxone — read more on the Chevron paraquat liability page. Your claim will be evaluated against both companies based on documented exposure during the relevant period.

Related reading: Litigation Overview, Full Timeline, Syngenta Corporate Accountability →